Your session is about to expire
← Back to Search
Kinesia 360 Parkinson's Monitoring Study
N/A
Waitlist Available
Led By Dustin Heldman, PhD
Research Sponsored by Great Lakes NeuroTechnologies Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
Kinesia 360 is an ambulatory symptom monitoring device for Parkinson's Disease (PD). The aim of this study is to investigate the impact, validation, and usability of the Kinesia 360 system.
Eligible Conditions
- Parkinson's Disease
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Kinesia 360 UsersExperimental Treatment1 Intervention
Parkinson's patients will be monitored continuously using wearable Kinesia 360 sensors.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Kinesia 360
2016
N/A
~50
Find a Location
Who is running the clinical trial?
University of RochesterOTHER
872 Previous Clinical Trials
550,052 Total Patients Enrolled
Johns Hopkins UniversityOTHER
2,339 Previous Clinical Trials
14,881,586 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,805 Previous Clinical Trials
28,194,812 Total Patients Enrolled
Prisma Health-UpstateOTHER
86 Previous Clinical Trials
43,781 Total Patients Enrolled
The Cleveland ClinicOTHER
1,057 Previous Clinical Trials
1,371,427 Total Patients Enrolled
Great Lakes NeuroTechnologies Inc.Lead Sponsor
19 Previous Clinical Trials
413 Total Patients Enrolled
University of South Carolina School of Medicine, GreenvilleUNKNOWN
1 Previous Clinical Trials
103 Total Patients Enrolled
Dustin Heldman, PhDPrincipal InvestigatorGreat Lakes NeuroTechnologies Inc.
3 Previous Clinical Trials
69 Total Patients Enrolled